Laboratory of Medicinal Chemistry and Drug Discovery, Pharmaceutical Research Institute (PRI), Albany College of Pharmacy and Health Sciences (ACPHS)
Dr. Mehdi Rajabi is Researcher at Pharmaceutical Research Institute (PRI), Albany College of Pharmacy and Health Sciences (ACPHS), Albany, New York. He obtained his Ph.D program in Molecular Medicine (focus on Medicinal Chemistry and Drug Discovery) from San Paolo Hospital, University of Milan, Italy (2007-2010). Before that he was Postdoctoral Scholar in RNA Nanotechnology at College of Pahrmacy, University of Kentucky, KY, USA (2013-2014) and Postdoctoral Fellow in the Department of PET-Nuclear Medicine at Università degli Studi di Milano-Bicocca, Italy (2012-2013) and Postdoc Fellow in Synthetic Medicinal Chemistry at Department of Pharmaceutical Science in the Università del Piemonte Orientale A. Avogadro, Novara, Italy (2011-2012).
His research interests involve collaborative research projects between chemistry and biology in order to design, synthesis, and evaluation of bioactive small molecules as drugs or biomarkers. In this regards organic chemistry lies at the heart of drug discovery and development and the current range of organic synthetic methodologies allows for the construction of unlimited libraries of small organic molecules for drug screening. As a medicinal chemist with a strong background in organic chemistry and various synthetic methodologies, he focused on design, synthesis and structural modification of different heterocycle compounds such as salicylaldoxime, benzofuran, quinolone, benzothiazole benzothiazol, chromene, thiopyran, resveratrol, naphthalene, and sphingosine derivatives, which are important intermediates for pharmaceutical, pesticides and other related industrial materials. He also was involved in several projects related to discovery of new drugs based on natural products and isolation of medicinal agents found in plants, as well as the creation of new synthetic drug compounds like cyctokinine, cyctokinine ribosides, aporphine alkaloids, anolides, flavonoids, and sesquiterpenes. A significant part of my research project here at Pharmaceutical Research Institute, PRI-ACPHS is devoted to structure–activity relationship (SAR) investigation of quinazoline derivatives in order to find a new class of NF-κB activation inhibitors. I am also working on design, synthesis and SAR analyze of thyroxin analogs for their ability to block angiogenesis in comparison to thyroid hormone antagonists (tetrac) with a site of action near the integrin αν-β3’s binding pocket. In other hands, He also works on development of new nanoparticle systems (based on nucleic acids, polymers, micelles and liposomes) that could improve chemotherapeutic delivery through increasing the solubility and sustaining of retention times